crystal violet drug
Evidence from:
primary |
all sources
Related entities (2)
| Subject | Relation | Object | p-value | Evidence |
|---|---|---|---|---|
| crystal violet | interacts_with | HCC | — | 1 |
| paraformaldehyde | associated_with | crystal violet | — | 1 |
Mentioned in (9)
Papers in which this entity is mentioned.
- Multigenerational cell tracking of DNA replication and heritable DNA damage. (2025)
- Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype. (2017)
- PGBD5 promotes site-specific oncogenic mutations in human tumors. (2017)
- Establishment of human iPSC-based models for the study and targeting of glioma initiating cells. (2016)
- A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. (2015)
- CtBP2 is an independent prognostic marker that promotes GLI1 induced epithelial-mesenchymal transition in hepatocellular carcinoma. (2015)
- PVT1 dependence in cancer with MYC copy-number increase. (2014)
- Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. (2014)
- Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. (2009)
Merged raw entities (2)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| crystal violet | drug | 9 | 12 |
| 0.5% crystal violet | drug | — | — |